作者
Teri E Klein, Jeffrey T Chang, Mildred K Cho, Katrina L Easton, Ray Fergerson, Micheal Hewett, Zhen Lin, Y Liu, S Liu, DE Oliver, DL Rubin, F Shafa, JM Stuart, RB Altman
发表日期
2001/3
来源
The pharmacogenomics journal
卷号
1
期号
3
页码范围
167-170
出版商
Nature Publishing Group
简介
Pharmacogenetics seeks to explain how people respond in different ways to the same drug treatment. A classic example of the importance of pharmacogenomics is the variation in individual responses to the anti-leukemia drug, 6-mercaptopurine. Most people metabolize the drug quickly. Some individuals, with a genetic variation for the enzyme thiopurine methyltransferase (TPMT), 1 do not. Consequently, they need lower doses of 6-mercaptopurine for effective treatment as normal doses can be lethal. One of the many promises of the human genome project is an ability to pharmacologically treat individuals in a more personalized rather than statistical manner.
Two independent sequence drafts of the human genome were recently completed and reported simultaneously in the literature. 2, 3 With these drafts in hand, and further refinement of these sequence maps expected in the future, scientists are presented with …
引用总数
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024441114132516234160755237121612129121715147
学术搜索中的文章
TE Klein, JT Chang, MK Cho, KL Easton, R Fergerson… - The pharmacogenomics journal, 2001